MT-125 with radiation and chemotherapy for newly diagnosed glioblastoma
Part of Cancer clinical trials.
This study tests whether a new drug called MT-125, combined with standard radiation and chemotherapy, is safe and effective for patients with a specific type of brain tumor (glioblastoma) that has a particular genetic feature (MGMT methylation). The goal is to see if this combination helps patients live longer without serious side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Newly diagnosed glioblastoma confirmed by biopsy or genetic testing, with specific genetic features (IDH wildtype and MGMT methylated)
- Able to perform daily activities with minimal assistance (ECOG score 0, 1, or 2)
- Normal blood counts, liver, and kidney function within the last 15 days
- Normal heart function and electrical activity (ejection fraction ≥55% and QTc ≤470 ms)
- Must not be pregnant or nursing, and willing to use effective contraception if able to have children
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding ruxolitinib, a targeted drug, to the standard radiation and chemotherapy for newly diagnosed glioblastoma. It aims to see if this combination helps people live longer without their cancer growing.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
This trial tests a new drug called MT-125 for people with a specific type of brain cancer called glioblastoma (GBM) that is IDH wildtype and MGMT unmethylated. The study will see if MT-125 is safe and tolerable, and how well it works.
This early-stage trial tests an experimental drug (BGB-58067) for people with a newly diagnosed glioblastoma that has a specific gene deletion (MTAP). It aims to see if the drug can shrink the tumor or slow its growth.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.